Correspondence to: Q.-T. Le, Department of Radiation Oncology, Stanford University, 875 Blake Wilbur Drive, MC 5847, Stanford, CA 94305-5847. E-mail: [email protected]Search for more papers by this author

Chad Tang MD, MS,

Chad Tang MD, MS

Department of Radiation Oncology, Stanford University, Stanford, California

Search for more papers by this author

Cato Chan BS,

Cato Chan BS

Department of Radiation Oncology, Stanford University, Stanford, California

Search for more papers by this author

Wen Jiang PhD,

Wen Jiang PhD

Department of Radiation Oncology, Stanford University, Stanford, California

Search for more papers by this author

James D. Murphy MD, MS,

James D. Murphy MD, MS

Department of Radiation Oncology, Stanford University, Stanford, California

Search for more papers by this author

Rie von Eyben MS,

Rie von Eyben MS

Department of Radiation Oncology, Stanford University, Stanford, California

Search for more papers by this author

A. Dimitrios Colevas MD,

A. Dimitrios Colevas MD

Division of Medical Oncology, Department of Medicine, Stanford University, Stanford, California

Search for more papers by this author

Harlan Pinto MD,

Harlan Pinto MD

Division of Medical Oncology, Department of Medicine, Stanford University, Stanford, California

Veterans Administration Palo Alto Heath Care System, Palo Alto, California

Search for more papers by this author

Nancy Lee–Enriquez RN,

Nancy Lee–Enriquez RN

Department of Radiation Oncology, Stanford University, Stanford, California

Search for more papers by this author

Christina Kong MD,

Christina Kong MD

Department of Pathology, Stanford University, Stanford, California

Search for more papers by this author

Quynh-Thu Le MD,

Corresponding Author

Quynh-Thu Le MD

Department of Radiation Oncology, Stanford University, Stanford, California

First published: 15 January 2014

https://doi.org/10.1002/hed.23609

Citations: 27

Share a link

Email
Wechat
Bluesky

Abstract

Background

The purpose of this study was to present our experience utilizing cetuximab and platinum-based concurrent chemoradiotherapy for the definitive treatment of head and neck squamous cell carcinoma (HNSCC).

Methods

Patients (n = 177) who received definitive concurrent chemoradiotherapy for HNSCC were stratified into 3 groups: receiving cetuximab monotherapy (n = 24), cetuximab and chemotherapy combination (n = 33), or platinum-based chemotherapy without cetuximab (n = 120). Primary endpoints were freedom from relapse, event-free survival, and overall survival (OS).

Results

Patients receiving cetuximab monotherapy were older with lower Karnofsky performance status (KPS) and higher Charlson comorbidity scores compared with those treated with combination cetuximab and chemotherapy or platinum-based concurrent chemoradiotherapy. Patients treated with platinum-based concurrent chemoradiotherapy exhibited significantly better freedom from relapse, event-free survival, and OS compared with those receiving cetuximab monotherapy or cetuximab and chemotherapy combination therapies (all p < .05). Differences between patients receiving cetuximab monotherapy and platinum-based concurrent chemoradiotherapy held on multivariate Cox regression.

Conclusion

This study suggests that platinum-based concurrent chemoradiotherapy is superior to cetuximab-based monotherapy for the definitive treatment of HNSCC. © 2014 Wiley Periodicals, Inc. Head Neck 37: 386–392, 2015

REFERENCES

1Pignon JP, le Maître A, Maillard E, Bourhis J; MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92: 4–14.
10.1016/j.radonc.2009.04.014
PubMed Web of Science® Google Scholar
2Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567–578.
10.1056/NEJMoa053422
CAS PubMed Web of Science® Google Scholar
3Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11: 21–28.
10.1016/S1470-2045(09)70311-0
CAS PubMed Web of Science® Google Scholar
4Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116–1127.
10.1056/NEJMoa0802656
CAS PubMed Web of Science® Google Scholar
5Curran D, Giralt J, Harari PM, et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol 2007; 25: 2191–2197.
10.1200/JCO.2006.08.8005
CAS PubMed Web of Science® Google Scholar
6Wong SJ, Harari PM, Garden AS, et al. Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN): analysis of chemoradiation treatment approaches in the United States. Cancer 2011; 117: 1679–1686.
10.1002/cncr.25721
PubMed Web of Science® Google Scholar
7 RTOG 1016: radiation therapy with cisplatin or cetuximab in treating patients with oropharyngeal cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT01302834. Accessed August 20, 2013.
Google Scholar
8Ang KK, Zhang Q, Rosenthal DI, et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III–IV head and neck squamous cell carcinomas (HNC). ASCO. J Clin Oncol 2011; 29(Suppl; abstract 5500).
PubMed Web of Science® Google Scholar
9 Radiation therapy and cisplatin or panitumumab in treating patients with locally advanced stage III or stage IV head and neck cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT00820248. Accessed August 20, 2013.
Google Scholar
10Koutcher L, Sherman E, Fury M, et al. Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2011; 81: 915–922.
10.1016/j.ijrobp.2010.07.008
CAS PubMed Web of Science® Google Scholar
11Caudell JJ, Sawrie SM, Spencer SA, et al. Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment. Int J Radiat Oncol Biol Phys 2008; 71: 676–681.
10.1016/j.ijrobp.2007.10.040
CAS PubMed Web of Science® Google Scholar
12Daly ME, Le QT, Maxim PG, et al. Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: clinical outcomes and patterns of failure. Int J Radiat Oncol Biol Phys 2010; 76: 1339–1346.
10.1016/j.ijrobp.2009.04.006
PubMed Web of Science® Google Scholar
13Kong CS, Narasimhan B, Cao H, et al. The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2009; 74: 553–561.
10.1016/j.ijrobp.2009.02.015
CAS PubMed Web of Science® Google Scholar
14Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373–383.
10.1016/0021-9681(87)90171-8
CAS PubMed Google Scholar
15Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24–35.
10.1056/NEJMoa0912217
CAS PubMed Web of Science® Google Scholar
16Kies MS, Holsinger FC, Lee JJ, et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol 2010; 28: 8–14.
10.1200/JCO.2009.23.0425
CAS PubMed Web of Science® Google Scholar
17Wanebo HJ, Ghebremichael MS, Burtness B, et al. Phase II evaluation of cetuximab (C225) combined with induction paclitaxel and carboplatin followed by C225, paclitaxel, carboplatin, and radiation for stage III/IV operable squamous cancer of the head and neck (ECOG, E2303). J Clin Oncol 2010; 25:abstract 6015.
Google Scholar
18Lefebvre JL, Pointreau Y, Rolland F, et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. J Clin Oncol 2013; 31: 853–859.
10.1200/JCO.2012.42.3988
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume37, Issue3

March 2015

Pages 386-392

Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer

Abstract

Background

Methods

Results

Conclusion

REFERENCES

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer

Abstract

Background

Methods

Results

Conclusion

REFERENCES

Citing Literature

References

Related

Information